Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: NMR Biomed. 2016 Jan 15;30(3):10.1002/nbm.3458. doi: 10.1002/nbm.3458

Figure 3.

Figure 3

Whole-body diffusion-weighted MRI (wbDW-MRI) is presented as an early indicator of response to systemic therapy in patients with lymphoma. (A) Image of a 48-year-old man diagnosed with diffuse large B-cell lymphoma obtained at baseline shows the ubiquitous involvement of lymph nodes (e.g. cervical and retroperitoneal, small arrows) and axillary regions (large arrows) with marked restriction of water diffusivity. A larger pelvic node (arrowhead) is also seen left of the midline. (B) At day 7 following the institution of chemotherapy with rituximab (anti-CD20 antibodies) + CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone), wbDW-MRI shows evident reduction in signal intensity in the cervical and retroperitoneal node regions (small arrows) and axillary region (large arrows) (from ADC = 0.90/0.33/0.67/0.61 to ADC = 1.66/0.73/1.36/1.22), with a corresponding increase in ADC (not shown), but a less marked response, in the pelvic node (arrowhead) (from ADC = 0.83/0.51 to ADC = 1.12/0.67) At the interim, the patient achieved complete remission. [Courtesy of ref. (59).]